Additional European Equity News

Atos (ATO FP) - Launches EUR 233mln capital increase. (Newswires) 

AstraZeneca (AZN LN) - Tezspire met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps. (Newswires) 

Bechtle (BEC8 GY) - Q3 (EUR): Revenue +2% Y/Y. No longer expect to acheive adj. forecast. 

Fincantieri (FCT IM) - Signs contract with Crystal worth between EUR 500mln. (Newswires) 

IAG (IAG LN) - Q3 (EUR): Revenue 9.33bln (Exp. 9.22bln). Adj. Op. 2.01bln (exp. 1.78bln), Adj. Net Income 1.44bln (exp. 1.32bln). Adjusts FY non-fuel costs to +2% (prev. guided "increase slighlty overall"). Load Factor 89.9%. Cuts FY24 capacity +6% (prev. guided +7%). Cuts FY24 Capex 3.1bln (prev. guided 3.7bln). (Newswires)

Indivior (INDV LN) - Responds to letter from Oaktree;  says board has engaged with Oaktree on value creation proposals. (Newswires) 

Reckitt (RKT LN) - CMA sets out concerns and solutions re. infant forumla market which appear to be attribuing to parents paying over the odds. Final report in Feb 2025. (Newswires) 

Rightmove (RMV LN) - Trading update (GBP): Narrows FY24 Revenue 390mln. Expects to see a modest acceleration in revenue growth in 2025.  (Newswires)  

Serco (SRP LN) - Unsuccesful in Australian immigration rebit. Guidance for 2024 remains unchanged. (Newswires) 

Vistry (VTY LN) - Trading update: Expects to deliver adj. PBT in FY24 of GBP 300mln. (Newswires) 

Zealand Pharma (ZEAL DC) initiated with Overweight at JPMorgan 

08 Nov 2024 - 07:02- EquitiesResearch Sheet- Source: Newsquawk